| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/29/2002 | WO2002065989A2 Aminoglycoside treatment for lysosomal storage diseases |
| 08/29/2002 | WO2002065986A2 Transporters comprising spaced arginine moieties |
| 08/29/2002 | WO2002065985A2 Methods of treating diabetes mellitus |
| 08/29/2002 | WO2002065943A2 Ocular tear growth factor-like protein |
| 08/29/2002 | WO2002050114A3 Modulation of atp-binding cassette transporter activity |
| 08/29/2002 | WO2002042438A3 Human kinases and polynucleotides encoding the same |
| 08/29/2002 | WO2002042316A3 Pna analogues |
| 08/29/2002 | WO2002041836A3 Antisense modulation of src-1 expression |
| 08/29/2002 | WO2002038759A3 Method for inducing apoptiosis |
| 08/29/2002 | WO2002036624A3 Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof |
| 08/29/2002 | WO2002034286B1 Methods for treating endocrine disorders |
| 08/29/2002 | WO2002033112A3 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | WO2002024235A3 Prochelators of radiometal labeled molecules |
| 08/29/2002 | WO2002022795A3 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002018622A3 TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) |
| 08/29/2002 | WO2002016426A3 Coaster, a human coactivator of steroid receptors |
| 08/29/2002 | WO2002016409A3 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 08/29/2002 | WO2002012460A3 Isolation of a human amine oxidase-like protein |
| 08/29/2002 | WO2002010403A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 08/29/2002 | WO2002010388A3 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| 08/29/2002 | WO2002010366A3 Methods and compositions for diagnosing and treating chromosome-18p related disorders |
| 08/29/2002 | WO2002008256A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 08/29/2002 | WO2002002774A3 32626, a human udp-glycosyltransferase and uses thereof |
| 08/29/2002 | WO2002000641A3 Spla2 inhibitors |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001095943A3 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 08/29/2002 | WO2001094388A3 Zcys6: a member of the cystatin superfamily |
| 08/29/2002 | WO2001092497A3 Human pancreatic islet glucose-6-phosphatase |
| 08/29/2002 | WO2001091808A3 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 08/29/2002 | WO2001090758A3 Diagnosis of alzheimer's disease ldl receptor protein-1 |
| 08/29/2002 | WO2001090157A3 98p7c3: homeodomain protein highly expressed in various cancers |
| 08/29/2002 | WO2001088135A3 G-protein coupled receptor proteins and nucleic acids encoding same |
| 08/29/2002 | WO2001087930A3 Human galanin receptor-like g protein coupled receptor |
| 08/29/2002 | WO2001087239A3 Methods of affecting laminin 5 processing |
| 08/29/2002 | WO2001085154A3 Method of treating immune pathologies with low dose estrogen |
| 08/29/2002 | WO2001085093A3 Compounds and methods for modulating cerebral amyloid angiopathy |
| 08/29/2002 | WO2001083769A3 Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis |
| 08/29/2002 | WO2001082975A3 Membrane-permeant peptide complexes for medical imaging |
| 08/29/2002 | WO2001079496A3 Ligand for herpes simplex virus entry mediator and methods of use |
| 08/29/2002 | WO2001079284A3 Therapeutic compounds and methods for formulating v3, a versican isoform |
| 08/29/2002 | WO2001077338A3 Human protein kinases and protein kinase-like enzymes |
| 08/29/2002 | WO2001070816A3 Ecdysone receptor-based inducible gene expression system |
| 08/29/2002 | WO2001068858A3 Human g protein-coupled receptors |
| 08/29/2002 | WO2001068848A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/29/2002 | WO2001068053A3 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 08/29/2002 | WO2001064903A3 Novel human transferase proteins and polynucleotides encoding the same |
| 08/29/2002 | WO2001061055A3 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/29/2002 | WO2001057206A3 Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| 08/29/2002 | WO2001053453A8 Novel bone marrow nucleic acids and polypeptides |
| 08/29/2002 | WO2001048164A3 Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| 08/29/2002 | WO2001042462A9 Phospholipase a2 inhibitory peptides from python reticulatus |
| 08/29/2002 | WO2001040293A9 Method of modulating proapoptotic and antiapoptotic pathways in cells |
| 08/29/2002 | WO2001027289A9 Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics |
| 08/29/2002 | WO2001012584A3 Pharmaceutical compounds |
| 08/29/2002 | WO2001007481A9 Antitumor antibodies, proteins, and uses thereof |
| 08/29/2002 | WO2001005427A9 Psca: prostate stem cell antigen and uses thereof |
| 08/29/2002 | WO2001004629A9 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 08/29/2002 | WO2001000247A9 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 08/29/2002 | WO2000066737A9 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY |
| 08/29/2002 | WO2000066709A9 Zymogen activation system |
| 08/29/2002 | WO2000063245A9 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 08/29/2002 | WO2000059515A9 Immunomodulating polymers |
| 08/29/2002 | WO2000056866A9 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 08/29/2002 | WO2000055330A9 Polysaturated fatty acid (pufa) elongase from caenorhabditis elegans |
| 08/29/2002 | WO2000053735A9 Methods for identifying modulators of synaptic plasticity and cell motility |
| 08/29/2002 | WO2000037502A9 Vascular endothelial cell growth factor antagonists and uses thereof |
| 08/29/2002 | WO2000034475A9 Grnf4, a gdnf-related neurotrophic factor |
| 08/29/2002 | WO2000034474A9 Growth factor homolog zvegf3 |
| 08/29/2002 | WO2000034447A9 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 08/29/2002 | WO2000033894A9 Collagen hemostatic foam |
| 08/29/2002 | WO2000032765A9 Ribozyme therapy for the treatment and/or prevention of restenosis |
| 08/29/2002 | WO1999064055A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors |
| 08/29/2002 | WO1999057280A9 Neisseria meningitidis antigens and compositions |
| 08/29/2002 | US20020120951 Transgenic mice containing FPR-RS4 gene disruptions |
| 08/29/2002 | US20020120948 Modulating gene expression by regulation of cell proliferation; regulated transgene expression in lymphocytes by selective increase in the number of lymphocytes upon exposure to an antigen |
| 08/29/2002 | US20020120475 System and method for arranging shipment and insurance for an item |
| 08/29/2002 | US20020120123 Human vascular endothelial growth factor 2 |
| 08/29/2002 | US20020120121 Antisense therapy of cancer; Inhibitors of Apoptosis Proteins (IAPs) and an additional related antiapoptotic protein, NAIP; |
| 08/29/2002 | US20020120120 Nucleic acid sequences of genes encoding high mobility group proteins and uses thereof |
| 08/29/2002 | US20020120106 Peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating immune response; antisense agents |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020120102 Native Arg-Gly-Asp (RGD) motif has been deleted or has been replaced by an amino acid sequence having no integrin- binding activity, or an integrin-binding amino acid sequence other than RGD which contains aspartic acid or glutamic acid |
| 08/29/2002 | US20020120101 Biosurfactants for blocking the interaction of a pathogen with a collagen receptor |
| 08/29/2002 | US20020120100 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents |
| 08/29/2002 | US20020120099 Novel cyclic tetrapeptide derivatives and pharmaceutical uses thereof |
| 08/29/2002 | US20020120098 Enhanced stimulation of erythropoiesis |
| 08/29/2002 | US20020120009 Compounds and compositions for delivering active agents |
| 08/29/2002 | US20020119998 Oxadiazole, thiadiazoles or triazole metal derivatives reacted with an amine containing aldehyde, deprotecting, coupling with an acid and oxidizing to create substituted oxadiazole, thiadiazole or triazole peptoids |
| 08/29/2002 | US20020119992 Anticoagulants |
| 08/29/2002 | US20020119985 Serine protease inhibitors |
| 08/29/2002 | US20020119956 Using thalidomine |
| 08/29/2002 | US20020119946 Formative agent of protein complex |
| 08/29/2002 | US20020119945 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/29/2002 | US20020119944 Use of Ulip-and/or Ulip2 in the treatment of myelin disorders |
| 08/29/2002 | US20020119943 Novel mammalian gene,bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes |
| 08/29/2002 | US20020119941 In-situ gel formation of pectin |
| 08/29/2002 | US20020119933 Administering ribose; cardiovascular disorders |
| 08/29/2002 | US20020119932 RGD-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects |
| 08/29/2002 | US20020119931 Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity |